Immunological responses in C3H/HeJ mice following nose-only inhalation exposure to different sizes of beryllium metal particles

Journal of Applied Toxicology

Volumn 29, Issue 1, 2009, Pages 61-68

  Salehi, Fariba ^b   Zayed, Joseph ^a   Audusseau, Séverine ^b   Muller, Caroline ^a   Truchon, Ginette ^c   Plamondon, Philippe ^d   L'Espérance, Gilles ^d   Chevalier, Gaston ^e   Mazer, Bruce ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c INSTITUT DE RECHERCHE ROBERT SAUVÉ EN SANTÉ ET EN SÉCURITÉ DU TRAVAIL   (Canada)

^d ÉCOLE POLYTECHNIQUE DE MONTRÉAL   (Canada)

^e UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

Beryllium metal; Cytokine secretion; Lung inflammation; Nose only inhalation; Particle size; T cells proliferation

Indexed keywords

BERYLLIUM; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BRONCHITIS; C3H MOUSE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; GRANULOMATOSIS; HISTOLOGY; IMMUNE RESPONSE; IMMUNOLOGY; INHALATION; LUNG LAVAGE; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PHENOTYPE; PRIORITY JOURNAL; SPLEEN CELL;

ADMINISTRATION, INHALATION; ANIMALS; BERYLLIUM; BRONCHITIS; CELL PROLIFERATION; CYTOKINES; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; GRANULOMA; INHALATION EXPOSURE; LUNG; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MALE; MICE; MICE, INBRED STRAINS; PARTICLE SIZE; SPLEEN;

ANIMALIA; MUS;

EID: 58149461409     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1383     Document Type: Article

References (32)

1. Amicosante M, Fontenot AP. 2006. T cell recognition in chronic beryllium disease. Clin. Immunol. 121: 134-143.
2. Day GA, Hoover MD, Stefaniak AB, Dickerson RM, Peterson EJ, Esmen NA, Scripsick RC. 2005. Bioavailability of beryllium oxide particles: an in vitro study in the murine J774A.1 macrophage cell line model. Exp. Lung Res. 31: 341-360.
3. Derelanko MJ. 1995. Risk assessment. In CRC Handbook of Toxicology, Derelanko MJ, Hollinger MA. CRC Press: Boca Raton, FL; 591-676.
4. Finch GL, Mewhinney JA, Hoover MD, Eidson AF, Haley PJ, Bice DE. 1990. Clearance, translocation, and excretion of beryllium following acute inhalation of beryllium oxide by beagle dogs. Fundam. Appl. Toxicol. 15(2): 231-241.
5. Finch GL, Hoover MD, Hahn FF, Nikula KJ, Belinsky SA, Haley PJ, Griffith WC. 1996. Animal models of beryllium-induced lung disease. Environ. Health Perspect. 104: 973-979.
6. Finch LM, Nikula KJ, Hoover MD. 1998. Dose-response relationships between inhaled beryllium metal and lung Toxicity in C3H Mice. Toxicol. Sc. 42: 36-48.
7. + T cells in patients with chronic beryllium disease. J. Clin. Invest. 110: 1473-1481.
8. Fontenot AP, Maier LA, Canavera SJ, Hendry-Hofer TB, Boguniewicz M, Barker EA, Newman LS, Kotzin BL, 2002b. Beryllium skin patch testing to analyze T cell stimulation and granulomatous inflammation in the lung. J. Immunol. 168: 3627-3634.
9. Fontenot AP, Palmer BE, Sullivan AK, Joslin FG, Wilson CC, Maier LS, Newman LS, Kotzin BL. 2005. Frequency of beryllium-specific, central memory CD4 T cells in blood determines proliferative response. J. Clin. Invest. 115: 2886-2893.
10. Haley PJ, Pavia KF, Swafford DS, Davila DR, Hoover MD, Finch GL. 1994. The comparative pulmonary toxicity of beryllium metal and beryllium oxide in cynomolgus monkeys. Immunopharmacol. Immunotoxicol. 16(4): 627-644.
11. Haley PJ, Finch GL, Hoover MD, Cuddihy RG. 1990. The acute toxicity of inhaled beryllium metal in rats. Fundam. Appl. Toxicol. 15(4): 767-778.
12. Henneberger PK, Cumro D, Deubner DD, Kent MS, MaCawley M, Kreiss K. 2001. Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant. Int. Arch. Occup. Environ. Health 74: 167-176.
13. Kent MS, Robins TG, Madl AK. 2001. Is total mass or mass of alveolar-deposited airborne particles of beryllium a better predictor of the prevalence of disease? A preliminary study of a beryllium processing facility. Appl. Occup. Environ. Hyg. 16(5): 539-558.
14. Kreiss K, Mroz MM, Zhen B, Wiedemann H, Barna B. 1997. Risks of beryllium disease related to work processes at a metal, alloy, and oxide production plant. Occup. Environ. Med. 54: 605-612.
15. Maier LA, McGrath DS, Sato H, Lympany P, Welsh K, Du Bois R, Silveira L, Fontenot AP, Sawyer RT, Wilcox E, Newman LS. 2003. Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease. J. Immunol. 171: 6910-6918.
16. Newman LS. 1996. Significance of the blood beryllium lymphocyte proliferation test (BeLPT). Environ. Health Perspect. 104: 953-956.
17. Newman LS, Balkissoon R, Daniloff E, Solida M, Mroz M. 1998. Rate of progression from beryllium sensitization to chronic beryllium disease is 9-19% per year. Am. J. Respir. Crit. Care Med. 157.
18. Nikula KJ, Swafford DS, Hoover MD, Tohulka MD, Finch GL. 1997. Chronic granulomatous pneumonia and lymphocytes responses induced by inhaled beryllium metal in A/J and C3H/HeJ mice. Toxicol. Pathol. 25: 2-12.
19. OSHA. 2005. Toxic and Hazardous Substances. 29CFR 1000, Table Z-1. Occupational Safety and Health Administration: Washington, DC.
20. Popper HH, 1999. Epitheliod cell granulomatosis of the lung: new insights and concepts. Sarcoidosis Vasc. Diffuse Lung Dis. 16: 32-46.
21. +4 T cells in patients with beryllium-induced disease. J. Allergy Clin. Immunol. 115: 1036-1042.
22. Raabe OG, Al-Bayati MA, Teague SV, Rasolt A. 1988. Regional deposition of inhaled monodisperse coarse and fine aerosol particles in small laboratory animals. Ann. Occup. Hyg. 32(suppl. 1): 53-63.
23. Rouleau M, Dion C, Plamondon P, L'Espérance G, Zayed J. 2005. Physical and chemical characterization of beryllium particles from several workplaces in Quebec, Canada - part a: time-of-flight secondary-ion mass spectroscopy. J. Toxicol. Env. Health 68: 1907-1916.
24. Saltini C, Winestock K, Kriby M, Pinkston P, Crystal RG. 1989. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. New Engl. J. Med. 320: 1103-1109.
25. Sawyer RT, Maier LA, Kittle LA, Newman LS. 2002. Chronic Beryllium disease: a model interaction between innate and acquired immunity. Int. Immunopharmac. 2: 249-261.
26. Schuler CR, Kent MS, Deubner DC, Berakis MT, McCawly M, Henneberger PK, Rossman MD, Kreiss K. 2005. Process-related risk of beryllium sensitization and disease in a copper-beryllium alloy facility. Am. J. Ind. Med. 47(3): 195-205.
27. Semenzato G, Adami F, Maschio N, Agostini C. 2000. Immune mechanisms in interstitial lung diseases. Allergy 55: 1103-1120.
28. Stefaniak AB, Hoover MD, Dickerson RM, Day GA, Breysse PN, Scripsick RC. 2007. Differences in estimates of size distribution of beryllium powder materials using phase contrast microscopy, scanning electron microscopy, and liquid suspension counter techniques. Part Fiber Toxicol. 4: 3.
29. Stefaniak AB, Gulmette RA, Day GA, Hoover MD, Breysse PN, Scripsick RC. 2005. Characterization of phagolysomal stimulant fluid for study of beryllium aerosol particle dissolution. Toxicol. In Vitro 19(1): 123-134.
30. Stiefel T, Schulze K, Zorn H, Tölg G. 1980. Toxicokinetic and toxicodynamic studies of beryllium. Arch Toxicol 45: 81-92.
31. Tinkle SS, Kittle LA, Schumacher BA, Newman LS. 1997. Beryllium induces IL-2 and IFN-γ in berylliosis. J. Immunol. 158: 518-526.
32. Williams DB, Carter CB. 1996. Transmission Electron Microscopy: A Textbook for Materials Science, 1st edn. Plenum Press: New York; 359.